SCHEMBL5887124

SCHEMBL5887124

Cc1nc(N2CCN(C(=O)Cc3ccccc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NC2CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPK8 P45983 1/20 0.43
GBA1 P04062 1/20 0.43
BRD4 O60885 2/20 0.42
JAK2 O60674 2/20 0.42
PARP1 P09874 2/20 0.40
KMT2A Q03164 3/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
CASP1 P29466 1/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
ME2 P23368 1/20 0.39
ME1 P48163 1/20 0.39
ME3 Q16798 1/20 0.39
CCNE1 P24864 2/20 0.39
CDK2 P24941 2/20 0.39
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887437 0.89 LMNA (0.57) LMNASMN1; SMN2KMT2AGAATSHR
SCHEMBL5886979 0.89 GBA1 (0.44) LMNASMN1; SMN2GBA1KMT2AGAA
SCHEMBL5887495 0.89 MEN1 (0.46) LMNASMN1; SMN2MAPK8GBA1KMT2A
SCHEMBL5887300 0.88 SMN1; SMN2 (0.43) LMNASMN1; SMN2MAPK8KMT2AGAA
SCHEMBL5887542 0.88 MAPK8 (0.45) LMNASMN1; SMN2MAPK8BRD4TSHR
SCHEMBL5887033 0.88 MAPK8 (0.40) LMNASMN1; SMN2MAPK8BRD4PARP1
SCHEMBL5887427 0.87 SMN1; SMN2 (0.46) LMNASMN1; SMN2MAPK8KMT2AGAA
SCHEMBL5886902 0.87 GBA1 (0.46) SMN1; SMN2GBA1KMT2AGAATSHR
SCHEMBL5887109 0.87 MAPT (0.39) LMNASMN1; SMN2MAPK8BRD4TSHR
SCHEMBL5887258 0.85 ALDH1A1 (0.45) SMN1; SMN2MAPK8GAATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP LMNA 711/4885SMN1; SMN2 2219/4885MAPK8 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.